Aegerion Pharmaceuticals
AEGR
AEGR was delisted on the 29th of November, 2016.
71 hedge funds and large institutions have $38.5M invested in Aegerion Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 19 increasing their positions, 30 reducing their positions, and 46 closing their positions.
57% more call options, than puts
Call options by funds: $590K | Put options by funds: $375K
30% less funds holding
Funds holding: 101 → 71 (-30)
37% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 30
65% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 46
66% less capital invested
Capital invested by funds: $113M → $38.5M (-$74.3M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$2.29M |
| 2 |
Renaissance Technologies
New York
|
+$1.36M |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$1.19M |
| 4 |
JG
Jefferies Group
New York
|
+$1.02M |
| 5 |
Two Sigma Investments
New York
|
+$584K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$4.08M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$2.18M |
| 3 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$1.7M |
| 4 |
AC
Armistice Capital
New York
|
-$1.6M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.31M |
AEGR Hedge Fund Activity: Q2 2016 in Review
71 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aegerion Pharmaceuticals (AEGR) for Q2 2016, worth a combined $38.5M — down 66% from $113M a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of AEGR and 16 opened new positions — a net loss of 30 holders — while 30 trimmed existing stakes and 19 added.
The largest buyer was Artal Group, opening a new position worth an estimated $2.29M. The largest seller was Putnam Investments, exiting entirely with an estimated $4.08M sold.
- 71 institutional investors held Aegerion Pharmaceuticals (AEGR) as of Q2 2016, down from 101 in Q1 2016.
- Funds reported $38.5M of Aegerion Pharmaceuticals stock for Q2 2016, down 66% quarter-over-quarter.
- 16 funds opened new Aegerion Pharmaceuticals positions in Q2 2016 and 46 closed out, a net change of -30 holders.
- The largest Aegerion Pharmaceuticals buyer in Q2 2016 was Artal Group, an estimated $2.29M added.
- The largest Aegerion Pharmaceuticals seller in Q2 2016 was Putnam Investments, an estimated $4.08M sold.
Based on aggregated 13F filings for Q2 2016.